Global Cord Blood (CO) Competitors

$0.95 0.00 (0.00%)

As of 05/15/2026

CO vs. MRAI, LXEO, AUTL, ANGO, and ZURA

Should you buy Global Cord Blood stock or one of its competitors? MarketBeat compares Global Cord Blood with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Global Cord Blood include Marpai (MRAI), Lexeo Therapeutics (LXEO), Autolus Therapeutics (AUTL), AngioDynamics (ANGO), and Zura Bio (ZURA).

How does Global Cord Blood compare to Marpai?

Marpai (NASDAQ:MRAI) and Global Cord Blood (NYSE:CO) are both small-cap miscellaneous health & allied services, not elsewhere classified industry companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, dividends, analyst recommendations, earnings and profitability.

Marpai has a beta of 4.38, indicating that its stock price is 338% more volatile than the broader market. Comparatively, Global Cord Blood has a beta of 0.16, indicating that its stock price is 84% less volatile than the broader market.

Global Cord Blood has higher revenue and earnings than Marpai. Marpai is trading at a lower price-to-earnings ratio than Global Cord Blood, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Marpai	$34.87M	0.21	-$28.75M	-$0.95	N/A
Global Cord Blood	$1.24B	0.09	$79.04M	$0.64	1.48

In the previous week, Marpai had 1 more articles in the media than Global Cord Blood. MarketBeat recorded 3 mentions for Marpai and 2 mentions for Global Cord Blood. Global Cord Blood's average media sentiment score of 0.37 beat Marpai's score of 0.00 indicating that Global Cord Blood is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Marpai	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Global Cord Blood	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Global Cord Blood has a net margin of 0.00% compared to Marpai's net margin of -85.70%.

Company	Net Margins	Return on Equity	Return on Assets
Marpai	-85.70%	N/A	-100.23%
Global Cord Blood	N/A	N/A	N/A

49.8% of Marpai shares are held by institutional investors. 46.1% of Marpai shares are held by company insiders. Comparatively, 0.5% of Global Cord Blood shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Global Cord Blood beats Marpai on 7 of the 12 factors compared between the two stocks.

How does Global Cord Blood compare to Lexeo Therapeutics?

Global Cord Blood (NYSE:CO) and Lexeo Therapeutics (NASDAQ:LXEO) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, dividends, earnings, valuation, profitability, risk and institutional ownership.

60.7% of Lexeo Therapeutics shares are owned by institutional investors. 0.5% of Global Cord Blood shares are owned by company insiders. Comparatively, 5.3% of Lexeo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Lexeo Therapeutics had 8 more articles in the media than Global Cord Blood. MarketBeat recorded 10 mentions for Lexeo Therapeutics and 2 mentions for Global Cord Blood. Lexeo Therapeutics' average media sentiment score of 0.86 beat Global Cord Blood's score of 0.37 indicating that Lexeo Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Global Cord Blood	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lexeo Therapeutics	1 Very Positive mention(s)	4 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lexeo Therapeutics has a consensus price target of $18.88, suggesting a potential upside of 270.83%. Given Lexeo Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Lexeo Therapeutics is more favorable than Global Cord Blood.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Global Cord Blood	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Lexeo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

Global Cord Blood has a beta of 0.16, suggesting that its stock price is 84% less volatile than the broader market. Comparatively, Lexeo Therapeutics has a beta of 1.52, suggesting that its stock price is 52% more volatile than the broader market.

Global Cord Blood's return on equity of 0.00% beat Lexeo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Global Cord Blood	N/A	N/A	N/A
Lexeo Therapeutics	N/A	-47.48%	-41.72%

Global Cord Blood has higher revenue and earnings than Lexeo Therapeutics. Lexeo Therapeutics is trading at a lower price-to-earnings ratio than Global Cord Blood, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Global Cord Blood	$1.24B	0.09	$79.04M	$0.64	1.48
Lexeo Therapeutics	N/A	N/A	-$99.96M	-$1.45	N/A

Summary

Lexeo Therapeutics beats Global Cord Blood on 9 of the 15 factors compared between the two stocks.

How does Global Cord Blood compare to Autolus Therapeutics?

Autolus Therapeutics (NASDAQ:AUTL) and Global Cord Blood (NYSE:CO) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, profitability, valuation, media sentiment, risk, institutional ownership and earnings.

72.8% of Autolus Therapeutics shares are held by institutional investors. 25.7% of Autolus Therapeutics shares are held by insiders. Comparatively, 0.5% of Global Cord Blood shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Autolus Therapeutics had 8 more articles in the media than Global Cord Blood. MarketBeat recorded 10 mentions for Autolus Therapeutics and 2 mentions for Global Cord Blood. Autolus Therapeutics' average media sentiment score of 0.56 beat Global Cord Blood's score of 0.37 indicating that Autolus Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Autolus Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Global Cord Blood	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Autolus Therapeutics currently has a consensus price target of $8.75, suggesting a potential upside of 436.81%. Given Autolus Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Autolus Therapeutics is more favorable than Global Cord Blood.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Autolus Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89
Global Cord Blood	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Autolus Therapeutics has a beta of 1.93, suggesting that its stock price is 93% more volatile than the broader market. Comparatively, Global Cord Blood has a beta of 0.16, suggesting that its stock price is 84% less volatile than the broader market.

Global Cord Blood has a net margin of 0.00% compared to Autolus Therapeutics' net margin of -311.98%. Global Cord Blood's return on equity of 0.00% beat Autolus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Autolus Therapeutics	-311.98%	-109.73%	-43.96%
Global Cord Blood	N/A	N/A	N/A

Global Cord Blood has higher revenue and earnings than Autolus Therapeutics. Autolus Therapeutics is trading at a lower price-to-earnings ratio than Global Cord Blood, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Autolus Therapeutics	$92.62M	4.68	-$287.53M	-$1.09	N/A
Global Cord Blood	$1.24B	0.09	$79.04M	$0.64	1.48

Summary

Autolus Therapeutics beats Global Cord Blood on 10 of the 17 factors compared between the two stocks.

How does Global Cord Blood compare to AngioDynamics?

Global Cord Blood (NYSE:CO) and AngioDynamics (NASDAQ:ANGO) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, earnings, risk, institutional ownership, profitability and media sentiment.

89.4% of AngioDynamics shares are owned by institutional investors. 0.5% of Global Cord Blood shares are owned by company insiders. Comparatively, 6.0% of AngioDynamics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Global Cord Blood and Global Cord Blood both had 2 articles in the media. AngioDynamics' average media sentiment score of 0.94 beat Global Cord Blood's score of 0.37 indicating that AngioDynamics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Global Cord Blood	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
AngioDynamics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Global Cord Blood has a beta of 0.16, suggesting that its stock price is 84% less volatile than the broader market. Comparatively, AngioDynamics has a beta of 0.37, suggesting that its stock price is 63% less volatile than the broader market.

Global Cord Blood has higher revenue and earnings than AngioDynamics. AngioDynamics is trading at a lower price-to-earnings ratio than Global Cord Blood, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Global Cord Blood	$1.24B	0.09	$79.04M	$0.64	1.48
AngioDynamics	$292.50M	1.52	-$33.99M	-$0.75	N/A

AngioDynamics has a consensus price target of $18.67, indicating a potential upside of 73.32%. Given AngioDynamics' stronger consensus rating and higher possible upside, analysts plainly believe AngioDynamics is more favorable than Global Cord Blood.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Global Cord Blood	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
AngioDynamics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

Global Cord Blood has a net margin of 0.00% compared to AngioDynamics' net margin of -10.01%. Global Cord Blood's return on equity of 0.00% beat AngioDynamics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Global Cord Blood	N/A	N/A	N/A
AngioDynamics	-10.01%	-4.66%	-3.08%

Summary

AngioDynamics beats Global Cord Blood on 9 of the 16 factors compared between the two stocks.

How does Global Cord Blood compare to Zura Bio?

Global Cord Blood (NYSE:CO) and Zura Bio (NASDAQ:ZURA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment and valuation.

Global Cord Blood's return on equity of 0.00% beat Zura Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Global Cord Blood	N/A	N/A	N/A
Zura Bio	N/A	-55.74%	-48.07%

Zura Bio has a consensus price target of $10.75, indicating a potential upside of 127.75%. Given Zura Bio's stronger consensus rating and higher possible upside, analysts plainly believe Zura Bio is more favorable than Global Cord Blood.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Global Cord Blood	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Zura Bio	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

Global Cord Blood has a beta of 0.16, suggesting that its share price is 84% less volatile than the broader market. Comparatively, Zura Bio has a beta of 0.09, suggesting that its share price is 91% less volatile than the broader market.

In the previous week, Global Cord Blood and Global Cord Blood both had 2 articles in the media. Zura Bio's average media sentiment score of 0.93 beat Global Cord Blood's score of 0.37 indicating that Zura Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Global Cord Blood	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Zura Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

61.1% of Zura Bio shares are owned by institutional investors. 0.5% of Global Cord Blood shares are owned by insiders. Comparatively, 14.2% of Zura Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Global Cord Blood has higher revenue and earnings than Zura Bio. Zura Bio is trading at a lower price-to-earnings ratio than Global Cord Blood, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Global Cord Blood	$1.24B	0.09	$79.04M	$0.64	1.48
Zura Bio	N/A	N/A	-$99.35M	-$1.09	N/A

Summary

Global Cord Blood and Zura Bio tied by winning 7 of the 14 factors compared between the two stocks.

Get Global Cord Blood News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CO vs. The Competition

Export

Metric	Global Cord Blood	health & allied services, not elsewhere classified Industry	Medical Sector	NYSE Exchange
Market Cap	$115.47M	$79.43M	$6.37B	$22.74B
Dividend Yield	N/A	N/A	2.80%	4.12%
P/E Ratio	1.48	0.74	20.66	29.73
Price / Sales	0.09	0.15	549.65	23.27
Price / Cash	4.19	4.19	42.43	24.79
Price / Book	0.15	0.15	9.87	4.60
Net Income	$79.04M	$25.15M	$3.57B	$1.06B
7 Day Performance	N/A	2.51%	0.23%	-2.27%
1 Month Performance	N/A	0.03%	-2.54%	-1.66%
1 Year Performance	-9.52%	-31.69%	33.54%	21.94%

Global Cord Blood Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CO Global Cord Blood	N/A	$0.95 flat	N/A	-9.5%	$115.47M	$1.24B	1.48	1,202	News Coverage
MRAI Marpai	N/A	$0.25 flat	N/A	-76.0%	$6.36M	$34.87M	N/A	150	News Coverage Gap Up
LXEO Lexeo Therapeutics	2.0708 of 5 stars	$5.85 +2.6%	$18.88 +222.6%	+57.1%	$459.42M	N/A	N/A	58	News Coverage Earnings Report Analyst Upgrade Gap Up
AUTL Autolus Therapeutics	3.2177 of 5 stars	$1.71 +6.6%	$8.50 +398.5%	+22.6%	$453.77M	$75.39M	N/A	330	News Coverage Earnings Report Analyst Forecast
ANGO AngioDynamics	2.8406 of 5 stars	$10.91 +0.0%	$18.67 +71.2%	+14.6%	$450.54M	$313.73M	N/A	760	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:CO) was last updated on 5/17/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Global Cord Blood (CO) Competitors

CO vs. MRAI, LXEO, AUTL, ANGO, and ZURA

How does Global Cord Blood compare to Marpai?

Summary

How does Global Cord Blood compare to Lexeo Therapeutics?

Summary

How does Global Cord Blood compare to Autolus Therapeutics?

Summary

How does Global Cord Blood compare to AngioDynamics?

Summary

How does Global Cord Blood compare to Zura Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CO vs. The Competition

Global Cord Blood Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Global Cord Blood (CO) Competitors

CO vs. MRAI, LXEO, AUTL, ANGO, and ZURA

How does Global Cord Blood compare to Marpai?

Which has more volatility and risk, MRAI or CO?

Which has preferable earnings and valuation, MRAI or CO?

Does the media prefer MRAI or CO?

Is MRAI or CO more profitable?

Do institutionals & insiders have more ownership in MRAI or CO?

Summary

How does Global Cord Blood compare to Lexeo Therapeutics?

Do institutionals and insiders hold more shares of CO or LXEO?

Does the media prefer CO or LXEO?

Do analysts rate CO or LXEO?

Which has more risk and volatility, CO or LXEO?

Is CO or LXEO more profitable?

Which has better earnings & valuation, CO or LXEO?

Summary

How does Global Cord Blood compare to Autolus Therapeutics?

Do insiders & institutionals hold more shares of AUTL or CO?

Does the media favor AUTL or CO?

Do analysts prefer AUTL or CO?

Which has more risk and volatility, AUTL or CO?

Is AUTL or CO more profitable?

Which has stronger earnings & valuation, AUTL or CO?

Summary

How does Global Cord Blood compare to AngioDynamics?

Do insiders and institutionals believe in CO or ANGO?

Does the media refer more to CO or ANGO?

Which has more volatility & risk, CO or ANGO?

Which has better valuation and earnings, CO or ANGO?

Do analysts recommend CO or ANGO?

Is CO or ANGO more profitable?

Summary

How does Global Cord Blood compare to Zura Bio?

Is CO or ZURA more profitable?

Do analysts prefer CO or ZURA?

Which has more risk & volatility, CO or ZURA?

Does the media prefer CO or ZURA?

Do institutionals and insiders believe in CO or ZURA?

Which has preferable earnings and valuation, CO or ZURA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CO vs. The Competition

Global Cord Blood Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools